Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against ACADIA Pharmaceuticals Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is ACADIA Pharmaceuticals Inc. (ACAD) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ACADIA Pharmaceuticals Inc. (“Acadia” or “the Company”) (NASDAQ: ACAD). Investors who purchased Acadia securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Acadia has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On September 24, 2026, Acadia issued a press release “announc[ing] Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).” Among other data, the Company disclosed that remlifanserin at 60 mg “narrowly missed” the primary endpoint of a clinical tool designed to measure the severity of the disease. Following this news, Acadia’s stock price fell $3.25 per share, or 12.78%, to close at $22.18 per share on September 24, 2026.
What Should ACADIA Pharmaceuticals Inc. (ACAD) Investors Do?
If you are aware of any facts relating to this investigation or purchased Acadia securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Did ACADIA Pharmaceuticals Inc. (ACAD) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”